CELL INTELLIGENCE · 肿瘤细胞治疗研究

OBJECTIVE: Besides breast and gastric cancer, HER2 amplification/mutation are also found in lung adenocarcinoma (LUAD). However, the correlation between HER2 variations and the phenotype of immunogenicity and tumor immune microenvironment (TIME) in LUAD compared with breast and gastric cancer has yet to be fully elucidated. METHODS: We integrated public databases (discovery set) and internal data (validated set) of 288 patients representing three distinct HER2 -altered tumors. Genomic data were used to identify somatic mutations, copy number variations, and calculate tumor mutational burden (TMB) and microsatellite instability score. RNA sequencing was conducted to estimate immune gene signatures and contents of tumor-infiltrating immune cell populations. Finally, IHC was used to determine PD-L1 expression and the tumoral-infiltration of immune cells in 50 HER2 -variant tumor specimens with no prior therapeutic regimens. RESULTS: Compared with HER2 -amplified breast and gastric cancers, patients with HER2 -amplified LUAD showed higher immunogenicity, mainly manifested in immune checkpoints expression and tissue/blood TMB. Additionally, HER2 -amplified LUAD exhibited an inflamed TIME with remarkably increased genes encoding HLAs, T-cell activity and immune cell-type, and accompanied with tumor-infiltrating lymphocytes. In LUAD, patients with HER2 amplification possessed higher tissue TMB than HER2 mutation, whereas no difference was observed in PD-L1 expression. HER2 amplification (primary) was associated with significantly higher PD-L1 expression and TMB than acquired HER2 amplification after resistance to EGFR-TKIs. CONCLUSION: Patients with HER2 -amplified LUAD have better immunogenicity and/or an inflamed TIME among HER2 -aberrant tumors. Our study may provide clues for establishing the benefits and uses of ICIs for patients with this disease.